These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38546326)

  • 1. Meta-DHGNN: method for CRS-related cytokines analysis in CAR-T therapy based on meta-learning directed heterogeneous graph neural network.
    Wei Z; Zhao C; Zhang M; Xu J; Xu N; Wu S; Xin X; Yu L; Feng W
    Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38546326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of CRS-associated cytokines in CAR-T therapy with meta-GNN and pathway crosstalk.
    Wei Z; Cheng Q; Xu N; Zhao C; Xu J; Kang L; Lou X; Yu L; Feng W
    BMC Bioinformatics; 2022 Sep; 23(1):373. PubMed ID: 36100873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
    Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y
    Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro.
    Zhang H; Lv X; Kong Q; Tan Y
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-14. PubMed ID: 35049413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
    Read JA; Rouce RH; Mo F; Mamonkin M; King KY
    Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis informed machine learning: Supporting cytokine storm detection during CAR-T cell Therapy.
    Bogatu A; Wysocka M; Wysocki O; Butterworth H; Pillai M; Allison J; Landers D; Kilgour E; Thistlethwaite F; Freitas A
    J Biomed Inform; 2023 Jun; 142():104367. PubMed ID: 37105509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
    Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
    Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
    Ding S; Chen R; Wang L; Zu C; Zhou X; Zhang J; Zhang M; Jin A; Wang T; Hu Y
    BMC Cancer; 2023 Nov; 23(1):1055. PubMed ID: 37919691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PrCRS: a prediction model of severe CRS in CAR-T therapy based on transfer learning.
    Wei Z; Zhao C; Zhang M; Xu J; Xu N; Wu S; Xin X; Yu L; Feng W
    BMC Bioinformatics; 2024 May; 25(1):197. PubMed ID: 38769505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
    Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
    [No Abstract]   [Full Text] [Related]  

  • 12. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
    Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
    Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma.
    Yang S; Xu J; Dai Y; Jin S; Sun Y; Li J; Liu C; Ma X; Chen Z; Chen L; Hou J; Mi JQ; Chen SJ
    Nat Commun; 2024 Jan; 15(1):360. PubMed ID: 38191582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators.
    Sachdeva M; Duchateau P; Depil S; Poirot L; Valton J
    J Biol Chem; 2019 Apr; 294(14):5430-5437. PubMed ID: 30804212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 16. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
    Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
    Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells.
    Wei Z; Xu J; Zhao C; Zhang M; Xu N; Kang L; Lou X; Yu L; Feng W
    Front Immunol; 2023; 14():1273507. PubMed ID: 37854590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome.
    Zheng N; Long Y; Bai Z; Li J; Wang H; Song DD; Liu HL; Shi JH; Zhao S
    J Transl Med; 2024 Jan; 22(1):58. PubMed ID: 38221609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
    Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA
    Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma.
    Wang X; Zhao L; Wang J; Yao Y; Wang J; Ji S; Hua T; Wang S; Cheng H; Shi M; Li Z; Zeng L; Zheng J; Xu K; Cao J
    Front Immunol; 2022; 13():814548. PubMed ID: 35572513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.